Effectiveness of Baofukang Suppository Adjuvant to Recombinant Human Interferon Alpha-2b in the Treatment of Cervical Columnar Epithelial Ectopia
Objective:To investigate the efficacy of recombinant human interferon α-2b combined with Baofukang suppository in the treatment of cervical columnar ectopy and its effect on serum inflammatory factors.Methods:From January 2021 to January 2023,67 patients with cervical columnar ectopy who were diagnosed and treated in the Department of Gynecology of Jian'an District Maternal and Child Health Hospital were selected as the research objects.According to the principle of random computer allocation,the patients were divided into 34 cases of Baofukang Suppository group and 33 cases of control group.The control group was treated with recombinant human interferon α-2b,and the Baofukang suppository group was treated with Baofukang suppository on the basis of the control group.The therapeutic effect,adverse reactions,expression of serum inflammatory factors and disappearance time of symptoms were compared between the two groups.Results:After treatment,the total effective rate of Baofukang suppository group was higher than that of control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the levels of serum interleukin-1β and interleukin-6 in the two groups were lower than those before treatment,and those in the Baofukang suppository group were lower than those in the control group(P<0.05).The disappearance time of vaginal bleeding,the disappearance time of cervical columnar epithelial ectopic surface and the disappearance time of abnormal leucorrhea in the Baofukang suppository group were shorter than those in the control group(P<0.05).Conclusion:Recombinant human interferon α-2b combined with Baofukang suppository in the treatment of cervical columnar epithelial ectopic can improve the overall therapeutic effect of patients,shorten the recovery time of patients,inhibit the expression of serum interleukin-1β and interleukin-6,and will not increase the incidence of adverse reactions.
Recombinant human interferon α-2bBaofukang suppositoryEctopic cervical columnar epithelium
NETL
NSTL
万方数据
